{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:39:17Z","timestamp":1789879157934,"version":"4.0.1"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T00:00:00Z","timestamp":1517875200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s11239-018-1623-4","type":"journal-article","created":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T03:37:07Z","timestamp":1517888227000},"page":"516-528","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms"],"prefix":"10.1007","volume":"45","author":[{"given":"Somedeb","family":"Ball","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyaw Zin","family":"Thein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Maiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Nugent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,6]]},"reference":[{"key":"1623_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision of the World Health Organization (WHO) classification of lymphoid neoplasms. Blood 127:2391\u20132405","journal-title":"Blood"},{"key":"1623_CR2","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/ajh.23690","volume":"89","author":"GJ Titmarsh","year":"2014","unstructured":"Titmarsh GJ, Duncombe AS, McMullin MF et al (2014) How common are myeloproliferative neoplasms? A systematic review and metaanalysis. Am J Hematol 89:581\u2013587","journal-title":"Am J Hematol"},{"key":"1623_CR3","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/ejh.12256","volume":"92","author":"O Moulard","year":"2014","unstructured":"Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA (2014) Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol 92:289\u2013297","journal-title":"Eur J Haematol"},{"key":"1623_CR4","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3324\/haematol.2012.064014","volume":"98","author":"M Maynadi\u00e9","year":"2013","unstructured":"Maynadi\u00e9 M, De Angelis R, Marcos-Gragera R et al (2013) Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study. Haematologica 98:230\u2013238","journal-title":"Haematologica"},{"key":"1623_CR5","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","volume":"30","author":"M Hultcrantz","year":"2012","unstructured":"Hultcrantz M, Kristinsson SY, Andersson TM-L et al (2012) Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol 30:2995\u20133001","journal-title":"J Clin Oncol"},{"key":"1623_CR6","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/BF02981937","volume":"73","author":"T Okamura","year":"2001","unstructured":"Okamura T, Kinukawa N, Niho Y et al (2001) Primary chronic myelofibrosis: clinical and prognostic evaluation in 336 Japanese patients. Int J Hematol 73:194\u2013198","journal-title":"Int J Hematol"},{"key":"1623_CR7","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1038\/sj.leu.2403902","volume":"19","author":"E Antonioli","year":"2005","unstructured":"Antonioli E, Guglielmelli P, Pancrazzi A et al (2005) Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 19:1847\u20131849","journal-title":"Leukemia"},{"key":"1623_CR8","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/leu.2010.69","volume":"24","author":"A Tefferi","year":"2010","unstructured":"Tefferi A (2010) Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 24:1128\u20131138","journal-title":"Leukemia"},{"key":"1623_CR9","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1182\/blood-2007-07-099184","volume":"110","author":"G Barosi","year":"2007","unstructured":"Barosi G, Bergamaschi G, Marchetti M et al (2007) Gruppo Italiano Malattie Ematologiche Maligne dell\u2019Adulto (GIMEMA) Italian Registry of Myelofibrosis. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 110:4030\u20134036","journal-title":"Blood"},{"key":"1623_CR10","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ et al (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369:2391\u20132405","journal-title":"N Engl J Med"},{"key":"1623_CR11","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/leu.2014.35","volume":"28","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Thiele J, Vannucchi AM, Barbui T (2014) An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia 28:1407\u20131413","journal-title":"Leukemia"},{"key":"1623_CR12","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y, Lee BH, Mercher T et al (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3:e270","journal-title":"PLoS Med"},{"key":"1623_CR13","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799\u2013807","journal-title":"N Engl J Med"},{"key":"1623_CR14","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366:787\u2013798","journal-title":"N Engl J Med"},{"key":"1623_CR15","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1055\/s-2007-976165","volume":"33","author":"A Tefferi","year":"2007","unstructured":"Tefferi A, Elliott M (2007) Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 33:313\u2013320","journal-title":"Semin Thromb Hemost"},{"key":"1623_CR16","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","volume":"115","author":"T Barbui","year":"2010","unstructured":"Barbui T, Carobbio A, Cervantes F et al (2010) Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 115:778\u2013782","journal-title":"Blood"},{"key":"1623_CR17","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","volume":"121","author":"H Gisslinger","year":"2013","unstructured":"Gisslinger H, Gotic M, Holowiecki J et al; ANAHYDRET Study Group (2013) Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood 121:1720\u20131728","journal-title":"Blood"},{"key":"1623_CR18","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","volume":"23","author":"R Marchioli","year":"2005","unstructured":"Marchioli R, Finazzi G, Landolfi R et al (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23:2224\u20132232","journal-title":"J Clin Oncol"},{"key":"1623_CR19","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/ajh.23217","volume":"87","author":"V Buxhofer-Ausch","year":"2012","unstructured":"Buxhofer-Ausch V, Gisslinger H, Thiele J et al (2012) Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early\/prefibrotic myelofibrosis: an international study of 264 patients. Am J Hematol 87:669\u2013672","journal-title":"Am J Hematol"},{"key":"1623_CR20","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","volume":"366","author":"PJ Campbell","year":"2005","unstructured":"Campbell PJ, Scott LM, Buck G et al (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366:1945\u20131953","journal-title":"Lancet"},{"key":"1623_CR21","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/ajh.23685","volume":"89","author":"M Montanaro","year":"2014","unstructured":"Montanaro M, Latagliata R, Cedrone M et al (2014) Thrombosis and survival in essential thrombocythemia: a regional study of 1,144 patients. Am J Hematol 89:542\u2013546","journal-title":"Am J Hematol"},{"key":"1623_CR22","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s11739-010-0413-6","volume":"5","author":"V Stefano De","year":"2010","unstructured":"De Stefano V, Martinelli I (2010) Splanchnic vein thrombosis: clinical presentation, risk factors and treatment. Intern Emerg Med 5:487\u2013494","journal-title":"Intern Emerg Med"},{"key":"1623_CR23","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1182\/blood-2012-01-407981","volume":"120","author":"T Barbui","year":"2012","unstructured":"Barbui T, Thiele J, Carobbio A et al (2012) Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early\/prefibrotic primary myelofibrosis. Blood 120:569\u2013571","journal-title":"Blood"},{"key":"1623_CR24","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1182\/blood-2016-09-728006","volume":"129","author":"L Skeith","year":"2017","unstructured":"Skeith L, Carrier M, Robinson SE, Alimam S, Rodger MA (2017) Risk of venous thromboembolism in pregnant women with essential thrombocythemia: a systematic review and meta-analysis. Blood 129:934\u2013939","journal-title":"Blood"},{"key":"1623_CR25","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.clml.2016.02.036","volume":"16","author":"I Khan","year":"2016","unstructured":"Khan I, Shergill A, Saraf SL et al (2016) Outcome disparities in Caucasian and non-Caucasian patients with myeloproliferative neoplasms. Clin Lymphoma Myeloma Leuk 16:350\u2013357","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1623_CR26","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","volume":"117","author":"A Carobbio","year":"2011","unstructured":"Carobbio A, Thiele J, Passamonti F et al (2011) Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 117:5857\u20135859","journal-title":"Blood"},{"key":"1623_CR27","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3324\/haematol.12053","volume":"93","author":"V Stefano De","year":"2008","unstructured":"De Stefano V, Za T, Rossi E et al (2008) Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 93:372\u2013380","journal-title":"Haematologica"},{"key":"1623_CR28","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/ajh.22024","volume":"86","author":"V Stefano De","year":"2011","unstructured":"De Stefano V, Rossi E, Za T et al (2011) JAK2 V617F mutational frequency in essential thrombocythemia associated with splanchnic or cerebral vein thrombosis. Am J Hematol 86:526\u2013528","journal-title":"Am J Hematol"},{"key":"1623_CR29","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.3324\/haematol.12970","volume":"93","author":"PD Ziakas","year":"2008","unstructured":"Ziakas PD (2008) Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain. Haematologica 93:1412\u20131414","journal-title":"Haematologica"},{"key":"1623_CR30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.leukres.2008.06.006","volume":"33","author":"IJ Dahabreh","year":"2008","unstructured":"Dahabreh IJ, Zoi K, Giannouli S, Zoi C, Loukopoulos D, Voulgarelis M (2008) Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res 33:67\u201373","journal-title":"Leuk Res"},{"key":"1623_CR31","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.thromres.2009.02.004","volume":"124","author":"F Lussana","year":"2009","unstructured":"Lussana F, Caberlon S, Pagani C, Kamphuisen PW, Buller HR, Cattaneo M (2009) Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. Thromb Res 124:409\u2013417","journal-title":"Thromb Res"},{"key":"1623_CR32","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.exphem.2009.06.006","volume":"37","author":"A Carobbio","year":"2009","unstructured":"Carobbio A, Finazzi G, Antonioli E et al (2009) JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol 37:1016\u20131021","journal-title":"Exp Hematol"},{"key":"1623_CR33","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajh.21593","volume":"85","author":"V Stefano De","year":"2010","unstructured":"De Stefano V, Za T, Rossi E et al (2010) Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. Am J Hematol 85:97\u2013100","journal-title":"Am J Hematol"},{"key":"1623_CR34","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","volume":"109","author":"R Landolfi","year":"2007","unstructured":"Landolfi R, Di Gennaro L, Barbui T et al (2007) European collaboration on low-dose aspirin in polycythemia vera (ECLAP). Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 109:2446\u20132452","journal-title":"Blood"},{"key":"1623_CR35","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1200\/JCO.2007.15.3569","volume":"26","author":"A Carobbio","year":"2008","unstructured":"Carobbio A, Antonioli E, Guglielmelli P et al (2008) Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol 26:2732\u20132736","journal-title":"J Clin Oncol"},{"key":"1623_CR36","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","volume":"120","author":"T Barbui","year":"2012","unstructured":"Barbui T, Finazzi G, Carobbio A et al (2012) Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET thrombosis). Blood 120:5128\u20135133","journal-title":"Blood"},{"key":"1623_CR37","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/bjh.12321","volume":"161","author":"A Alvarez-Larr\u00e1n","year":"2013","unstructured":"Alvarez-Larr\u00e1n A, Pereira A, Arellano-Rodrigo E, Hern\u00e1ndez-Boluda JC, Cervantes F, Besses C (2013) Cytoreduction plus low-dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high-risk essential thrombocythaemia: an observational study. Br J Haematol 161:865\u2013871","journal-title":"Br J Haematol"},{"key":"1623_CR38","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00277-015-2330-2","volume":"94","author":"JC Hern\u00e1ndez-Boluda","year":"2015","unstructured":"Hern\u00e1ndez-Boluda JC, Arellano-Rodrigo E, Cervantes F et al (2015) Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia. Ann Hematol 94:911\u2013918","journal-title":"Ann Hematol"},{"key":"1623_CR39","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/ejh.12806","volume":"98","author":"P Dombi","year":"2017","unstructured":"Dombi P, Ill\u00e9s \u00c1, Demeter J et al (2017) Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin. Eur J Haematol 98:106\u2013111","journal-title":"Eur J Haematol"},{"key":"1623_CR40","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1097\/MBC.0000000000000446","volume":"27","author":"BT Samuelson","year":"2016","unstructured":"Samuelson BT, Vesely SK, Chai-Adisaksopha C, Scott BL, Crowther M, Garcia D (2016) The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis. Blood Coagul Fibrinolysis 27:648\u2013652","journal-title":"Blood Coagul Fibrinolysis"},{"key":"1623_CR41","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/01.moh.0000190107.54790.de","volume":"13","author":"V Afshar-Kharghan","year":"2006","unstructured":"Afshar-Kharghan V, Thiagarajan P (2006) Leukocyte adhesion and thrombosis. Curr Opin Hematol 13:34\u201339","journal-title":"Curr Opin Hematol"},{"key":"1623_CR42","doi-asserted-by":"publisher","first-page":"48635","DOI":"10.1074\/jbc.M208877200","volume":"50","author":"VP Yakubenko","year":"2002","unstructured":"Yakubenko VP, Lishko VK, Lam SC-T, Ugarova TP (2002) A molecular basis for integrin aMb2 ligand binding promiscuity. J Biol Chem 50:48635\u201348642","journal-title":"J Biol Chem"},{"key":"1623_CR43","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","volume":"21","author":"AM Vannucchi","year":"2007","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P et al (2007) Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 21:1952\u20131959","journal-title":"Leukemia"},{"key":"1623_CR44","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1182\/blood-2005-09-3826","volume":"107","author":"F Passamonti","year":"2006","unstructured":"Passamonti F, Rumi E, Pietra D et al (2006) Relation between JAK2(V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 107:3676\u20133682","journal-title":"Blood"},{"key":"1623_CR45","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.thromres.2011.10.010","volume":"129","author":"C Cerletti","year":"2012","unstructured":"Cerletti C, Tamburrelli C, Izzi B, Gianfagna F, de Gaetano G (2012) Platelet\u2013leukocyte interactions in thrombosis. Thromb Res 129:263\u2013266","journal-title":"Thromb Res"},{"key":"1623_CR46","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood.V96.13.4261","volume":"96","author":"A Falanga","year":"2000","unstructured":"Falanga A, Marchetti M, Evangelista V et al (2000) Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 96:4261\u20134266","journal-title":"Blood"},{"key":"1623_CR47","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1126\/science.1092385","volume":"303","author":"V Brinkmann","year":"2004","unstructured":"Brinkmann V, Reichard U, Goosmann C et al (2004) Neutrophil extracellular traps kill bacteria. Science 303:1532\u20131535","journal-title":"Science"},{"key":"1623_CR48","doi-asserted-by":"publisher","first-page":"15880","DOI":"10.1073\/pnas.1005743107","volume":"107","author":"TA Fuchs","year":"2010","unstructured":"Fuchs TA, Brill A, Duerschmied D et al (2010) Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA 107:15880\u201315885","journal-title":"Proc Natl Acad Sci USA"},{"key":"1623_CR49","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1538-7836.2011.04544.x","volume":"10","author":"A Brill","year":"2012","unstructured":"Brill A, Fuchs TA, Savchenko AS et al (2012) Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost 10:136\u2013144","journal-title":"J Thromb Haemost"},{"key":"1623_CR50","doi-asserted-by":"publisher","first-page":"13076","DOI":"10.1073\/pnas.1200419109","volume":"109","author":"M Demers","year":"2012","unstructured":"Demers M, Krause DS, Schatzberg D et al (2012) Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci USA 109:13076\u201313081","journal-title":"Proc Natl Acad Sci USA"},{"key":"1623_CR51","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1365-2141.2006.06430.x","volume":"136","author":"M Nisio Di","year":"2007","unstructured":"Di Nisio M, Barbui T, Di Gennaro L et al (2007) European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP) Investigators. The haematocrit and platelet target in polycythemia vera. Br J Haematol 136:249\u2013259","journal-title":"Br J Haematol"},{"key":"1623_CR52","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R, Finazzi G, Specchia G et al; CYTO-PV Collaborative Group (2013) Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 368:22\u201333","journal-title":"N Engl J Med"},{"key":"1623_CR53","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.1182\/blood-2001-12-0349","volume":"100","author":"JL Spivak","year":"2002","unstructured":"Spivak JL (2002) Polycythemia vera: myths, mechanisms, and management. Blood 100:4272\u20134290","journal-title":"Blood"},{"key":"1623_CR54","doi-asserted-by":"publisher","first-page":"64113","DOI":"10.1063\/1.4833975","volume":"7","author":"H Chen","year":"2013","unstructured":"Chen H, Angerer JI, Napoleone M et al (2013) Hematocrit and flow rate regulate the adhesion of platelets to von Willebrand factor. Biomicrofluidics 7:64113","journal-title":"Biomicrofluidics"},{"issue":"Suppl. 2","key":"1623_CR55","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/S0049-3848(10)70151-1","volume":"127","author":"BP Nuyttens","year":"2011","unstructured":"Nuyttens BP, Thijs T, Deckmyn H, Broos K (2011) Platelet adhesion to collagen. Thromb Res 127(Suppl. 2):S26\u2013S29","journal-title":"Thromb Res"},{"key":"1623_CR56","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1161\/01.ATV.17.4.646","volume":"17","author":"PA Holme","year":"1997","unstructured":"Holme PA, Orvim U, Hamers MJ et al (1997) Shear induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis. Arterioscler Thromb Vasc Biol 17:646\u2013653","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1623_CR57","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1182\/blood-2012-07-440487","volume":"121","author":"M Grandis De","year":"2013","unstructured":"De Grandis M, Cambot M, Wautier MP et al (2013) JAK2V617F activates Lu\/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1\/Akt pathway. Blood 121:658\u2013665","journal-title":"Blood"},{"key":"1623_CR58","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1182\/blood-2006-05-025544","volume":"108","author":"A Tefferi","year":"2006","unstructured":"Tefferi A, Gangat N, Wolanskyj AP (2006) Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter? Blood 108:2493\u20132494","journal-title":"Blood"},{"key":"1623_CR59","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/ajh.2830490406","volume":"49","author":"G Castaman","year":"1995","unstructured":"Castaman G, Lattuada A, Ruggeri M, Tosetto A, Mannucci PM, Rodeghiero F (1995) Platelet von Willebrand factor abnormalities in myeloproliferative syndromes. Am J Hematol 49:289\u2013293","journal-title":"Am J Hematol"},{"key":"1623_CR60","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s12185-014-1673-0","volume":"100","author":"J Kissova","year":"2014","unstructured":"Kissova J, Bulikova A, Ovesna P, Bourkova L, Penka M (2014) Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR\/ABL-negative myeloproliferative neoplasms. Int J Hematol 100:429\u2013436","journal-title":"Int J Hematol"},{"key":"1623_CR61","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.leukres.2016.04.004","volume":"46","author":"L Gugliotta","year":"2016","unstructured":"Gugliotta L, Iurlo A, Gugliotta G, Tieghi A et al (2016) Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms. Leuk Res 46:18\u201325","journal-title":"Leuk Res"},{"key":"1623_CR62","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1055\/s-2006-949664","volume":"32","author":"JJ Michiels","year":"2006","unstructured":"Michiels JJ, Berneman Z, Schroyens W et al (2006) The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost 32:589\u2013604","journal-title":"Semin Thromb Hemost"},{"key":"1623_CR63","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/(SICI)1096-8652(199711)56:3<168::AID-AJH6>3.0.CO;2-W","volume":"56","author":"A Regev","year":"1997","unstructured":"Regev A, Stark P, Blickstein D et al (1997) Thrombotic complications in essential thrombocythemia with relatively low platelet counts. Am J Hematol 56:168\u2013172","journal-title":"Am J Hematol"},{"key":"1623_CR64","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/ejh.12759","volume":"97","author":"V Buxhofer-Ausch","year":"2016","unstructured":"Buxhofer-Ausch V, Steurer M, Sormann S et al (2016) Influence of platelet and white blood cell counts on major thrombosis\u2014analysis from a patient registry in essential thrombocythemia. Eur J Haematol 97:511\u2013516","journal-title":"Eur J Haematol"},{"key":"1623_CR65","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s00277-016-2812-x","volume":"95","author":"C Augello","year":"2016","unstructured":"Augello C, Cattaneo D, Bucelli C et al (2016) CD18 promoter methylation is associated with a higher risk of thrombotic complications in primary myelofibrosis. Ann Hematol 95:1965\u20131969","journal-title":"Ann Hematol"},{"key":"1623_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/cshperspect.a006429","volume":"2","author":"WC Aird","year":"2012","unstructured":"Aird WC (2012) Endothelial cell heterogeneity. Cold Spring Harb Perspect Med 2:1\u201313","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1623_CR67","first-page":"3527","volume":"91","author":"DB Cines","year":"1998","unstructured":"Cines DB, Pollak ES, Buck CA et al (1998) Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 91:3527\u20133561","journal-title":"Blood"},{"key":"1623_CR68","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1146\/annurev.iy.11.040193.004003","volume":"11","author":"MP Bevilacqua","year":"1993","unstructured":"Bevilacqua MP (1993) Endothelial-leukocyte adhesion molecules. Ann Rev Immunol 11:767\u2013804","journal-title":"Ann Rev Immunol"},{"key":"1623_CR69","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1164\/ajrccm.163.1.9912036","volume":"163","author":"M Mutunga","year":"2001","unstructured":"Mutunga M, Fulton B, Bullock R et al (2001) Circulating endothelial cells in patients with septic shock. Am J Respir Crit Care Med 163:195\u2013200","journal-title":"Am J Respir Crit Care Med"},{"key":"1623_CR70","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1182\/blood-2003-10-3479","volume":"103","author":"A Woywodt","year":"2004","unstructured":"Woywodt A, Scheer J, Hambach L et al (2004) Circulating endothelial cells as a marker of endothelial damage in allogeneic hematopoietic stem cell transplantation. Blood 103:3603\u20133605","journal-title":"Blood"},{"key":"1623_CR71","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1182\/blood.V97.11.3658","volume":"97","author":"P Mancuso","year":"2001","unstructured":"Mancuso P, Burlini A, Pruneri G et al (2001) Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 97:3658\u20133661","journal-title":"Blood"},{"key":"1623_CR72","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1161\/01.RES.0000246095.90247.d4","volume":"99","author":"S Wassmann","year":"2006","unstructured":"Wassmann S, Werner N, Czech T, Nickenig G (2006) Improvement of endothelial function by systemic transfusion of vascular progenitor cells. Circ Res 99:e74\u2013e83","journal-title":"Circ Res"},{"key":"1623_CR73","doi-asserted-by":"publisher","first-page":"e81574","DOI":"10.1371\/journal.pone.0081574","volume":"8","author":"C Torres","year":"2013","unstructured":"Torres C, Fonseca AM, Leander M et al (2013) Circulating endothelial cells in patients with venous thromboembolism and myeloproliferative neoplasms. PLoS ONE 8:e81574","journal-title":"PLoS ONE"},{"key":"1623_CR74","doi-asserted-by":"publisher","first-page":"e15277","DOI":"10.1371\/journal.pone.0015277","volume":"5","author":"V Rosti","year":"2010","unstructured":"Rosti V, Bonetti E, Bergamaschi G et al; AGIMM Investigators (2010) High frequency of endothelial colony forming cells marks a nonactive myeloproliferative neoplasm with high risk of splanchnic vein thrombosis. PLoS ONE 5:e15277","journal-title":"PLoS ONE"},{"key":"1623_CR75","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1182\/blood-2006-08-043471","volume":"109","author":"MC Yoder","year":"2007","unstructured":"Yoder MC, Mead LE, Prater D et al (2007) Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem\/progenitor cell principals. Blood 109:1801\u20131809","journal-title":"Blood"},{"key":"1623_CR76","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1182\/blood-2010-07-297598","volume":"117","author":"L Teofili","year":"2011","unstructured":"Teofili L, Martini M, Iachininoto MG et al (2011) Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms. Blood 117:2700\u20132707","journal-title":"Blood"},{"key":"1623_CR77","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","volume":"118","author":"AG Fleischman","year":"2011","unstructured":"Fleischman AG, Aichberger KJ, Luty SB et al (2011) TNF\u03b1 facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood 118:6392\u20136398","journal-title":"Blood"},{"key":"1623_CR78","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/2159-8290.CD-14-0736","volume":"5","author":"M Kleppe","year":"2015","unstructured":"Kleppe M, Kwak M, Koppikar P et al (2015) JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov 5:316\u2013331","journal-title":"Cancer Discov"},{"key":"1623_CR79","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1161\/ATVBAHA.110.207415","volume":"31","author":"H Ait-Oufella","year":"2011","unstructured":"Ait-Oufella H, Taleb S, Mallat Z, Tedgui A (2011) Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol 31:969\u2013979","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1623_CR80","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1093\/cvr\/cvn120","volume":"79","author":"R Kleemann","year":"2008","unstructured":"Kleemann R, Zadelaar S, Kooistra T (2008) Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res 79:360\u2013376","journal-title":"Cardiovasc Res"},{"key":"1623_CR81","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3324\/haematol.2010.031070","volume":"96","author":"T Barbui","year":"2011","unstructured":"Barbui T, Carobbio A, Finazzi G et al; AGIMM and IIC Investigators (2011) Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica 96:315\u2013318","journal-title":"Haematologica"},{"key":"1623_CR82","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1161\/CIRCRESAHA.108.183905","volume":"104","author":"A Eisenreich","year":"2009","unstructured":"Eisenreich A, Bogdanov VY, Zakrzewicz A et al (2009) Cdc2-like kinases and DNA topoisomerase regulate alternative splicing of tissue factor in human endothelial cells. Circ Res 104:589\u2013599","journal-title":"Circ Res"},{"key":"1623_CR83","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1016\/j.febslet.2009.07.037","volume":"583","author":"Y Chen","year":"2009","unstructured":"Chen Y, Wang J, Yao Y et al (2009) Crp regulates the expression and activity of tissue factor as well as tissue factor pathway inhibitor via nf-kappab and erk \u00bd mapk pathway. FEBS Lett 583:2811\u20132818","journal-title":"FEBS Lett"},{"key":"1623_CR84","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1161\/CIRCULATIONAHA.105.553735","volume":"112","author":"J Steffel","year":"2005","unstructured":"Steffel J, Akhmedov A, Greutert H, Luscher TF, Tanner FC (2005) Histamine induces tissue factor expression: implications for acute coronary syndromes. Circulation 112:341\u2013349","journal-title":"Circulation"},{"key":"1623_CR85","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1182\/blood.V97.6.1697","volume":"97","author":"H Kawano","year":"2001","unstructured":"Kawano H, Tsuji H, Nishimura H, Kimura S, Yano S, Ukimura N et al (2001) Serotonin induces the expression of tissue factor and plasminogen activator inhibitor-1 in cultured rat aortic endothelial cells. Blood 97:1697\u20131702","journal-title":"Blood"},{"key":"1623_CR86","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.leukres.2016.04.016","volume":"48","author":"P Rajnics","year":"2016","unstructured":"Rajnics P, Kellner \u00c1, Kar\u00e1di \u00c9 et al (2016) Increased Lipocalin 2 level may have important role in thrombotic events in patients with polycythemia vera and essential thrombocythemia. Leuk Res 48:101\u2013106","journal-title":"Leuk Res"},{"key":"1623_CR87","first-page":"555","volume":"122","author":"F Dignat George","year":"2008","unstructured":"Dignat George F (2008) Microparticles in vascular diseases. Thromb Res 122:555\u2013559","journal-title":"Thromb Res"},{"key":"1623_CR88","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.thromres.2008.06.006","volume":"123","author":"S Nomura","year":"2008","unstructured":"Nomura S, Ozaki Y, Ikeda Y (2008) Function and role of microparticles in various clinical settings. Thromb Res 123:8\u201323","journal-title":"Thromb Res"},{"key":"1623_CR89","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1160\/TH08-08-0521","volume":"101","author":"L Burnier","year":"2009","unstructured":"Burnier L, Fontana P, Kwak BR, Angelillo-Scherrer A (2009) Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost 101:439\u2013451","journal-title":"Thromb Haemost"},{"key":"1623_CR90","doi-asserted-by":"publisher","first-page":"911","DOI":"10.3324\/haematol.13774","volume":"94","author":"MC Trappenburg","year":"2009","unstructured":"Trappenburg MC, van Schilfgaarde M, Marchetti M et al (2009) Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocytopenia. Haematologica 94:911\u2013918","journal-title":"Haematologica"},{"key":"1623_CR91","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s12185-017-2302-5","volume":"106","author":"Y Taniguchi","year":"2017","unstructured":"Taniguchi Y, Tanaka H, Luis EJ et al (2017) Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms. Int J Hematol 106:691\u2013703","journal-title":"Int J Hematol"},{"key":"1623_CR92","doi-asserted-by":"crossref","unstructured":"Stein BL, McMahon B, Weiss I et al (2012) Tissue-factor bearing microparticles and thrombotic risk in the myeloproliferative neoplasms. ASH annual meeting abstracts 2012 [abstract 1145]","DOI":"10.1182\/blood.V120.21.1145.1145"},{"key":"1623_CR93","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/ajh.23590","volume":"89","author":"M Marchetti","year":"2014","unstructured":"Marchetti M, Tartari CJ, Russo L et al (2014) Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia. Am J Hematol 89:68\u201373","journal-title":"Am J Hematol"},{"key":"1623_CR94","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.thromres.2010.06.025","volume":"126","author":"J Duchemin","year":"2010","unstructured":"Duchemin J, Ugo V, Ianotto JC, Lecucq L, Mercier B, Abgrall JF (2010) Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms. Thromb Res 126:238\u2013242","journal-title":"Thromb Res"},{"key":"1623_CR95","doi-asserted-by":"crossref","unstructured":"Han Y, Zhao S, ZhangW, Cen J, Zhang W, Qiu H et al (2013) Clinical significance of circulating microparticles in Ph-myeloproliferative neoplasms (MPN). Blood (ASH Annual Meeting Abstracts), 122; 2013 [abstract 2368]","DOI":"10.1182\/blood.V122.21.2368.2368"},{"key":"1623_CR96","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1161\/CIRCRESAHA.110.233056","volume":"108","author":"AP Owens III","year":"2011","unstructured":"Owens AP III, Mackman N (2011) Microparticles in hemostasis and thrombosis. Circ Res 108:1284\u20131297","journal-title":"Circ Res"},{"key":"1623_CR97","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1055\/s-0030-1267040","volume":"36","author":"NS Key","year":"2010","unstructured":"Key NS, Mackman N (2010) Tissue factor and its measurement in whole blood, plasma, and microparticles. Semin Thromb Hemost 36:865\u2013875","journal-title":"Semin Thromb Hemost"},{"key":"1623_CR98","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1161\/ATVBAHA.107.141911","volume":"27","author":"N Mackman","year":"2007","unstructured":"Mackman N, Tilley RE, Key NS (2007) Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol 27:1687\u20131693","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1623_CR99","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1111\/j.1538-7836.2012.04758.x","volume":"10","author":"PEJ Meijden Van Der","year":"2012","unstructured":"Van Der Meijden PEJ, Van Schilfgaarde M, Van Oerle R, Renn ET, Ten Cate H, Spronk HMH (2012) Platelet- and erythrocyte-derived microparticles trigger thrombin generation via factor XIIa. J Thromb Haemost 10:1355\u20131362","journal-title":"J Thromb Haemost"},{"key":"1623_CR100","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.molmed.2004.02.008","volume":"10","author":"B Furie","year":"2004","unstructured":"Furie B, Furie BC (2004) Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med 10:171\u2013178","journal-title":"Trends Mol Med"},{"key":"1623_CR101","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1046\/j.1365-2141.2000.02030.x","volume":"110","author":"MK Jensen","year":"2000","unstructured":"Jensen MK, de Nully Brown P, Lund BV, Nielsen OJ, Hasselbalch HC (2000) Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol 110:116\u2013124","journal-title":"Br J Haematol"},{"key":"1623_CR102","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/j.1365-2141.2004.05032.x","volume":"126","author":"P Andr\u00e9","year":"2004","unstructured":"Andr\u00e9 P (2004) P-selectin in haemostasis. Br J Haematol 126:298\u2013306","journal-title":"Br J Haematol"},{"key":"1623_CR103","first-page":"169","volume":"91","author":"E Arellano-Rodrigo","year":"2006","unstructured":"Arellano-Rodrigo E, Alvarez-Larr\u00e1n A, Reverter JC, Villamor N, Colomer D, Cervantes F (2006) Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 91:169\u2013175","journal-title":"Haematologica"},{"key":"1623_CR104","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.thromres.2013.05.003","volume":"132","author":"M Panova-Noeva","year":"2013","unstructured":"Panova-Noeva M, Marchetti M, Russo L et al (2013) ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera. Thromb Res 132:88\u201393","journal-title":"Thromb Res"},{"key":"1623_CR105","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/ajh.21974","volume":"86","author":"M Panova-Noeva","year":"2011","unstructured":"Panova-Noeva M, Marchetti M, Spronk HM et al (2011) Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera. Am J Hematol 86:337\u2013342","journal-title":"Am J Hematol"},{"key":"1623_CR106","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1097\/MBC.0000000000000551","volume":"27","author":"G Gadomska","year":"2016","unstructured":"Gadomska G, Stankowska K, Boinska J, Bartoszewska-Kubiak A, Haus O, Ro\u015b\u0107 D (2016) Activation of the tissue factor-dependent extrinsic pathway and its relation to JAK2 V617F mutation status in patients with essential thrombocythemia. Blood Coagul Fibrinolysis 27:817\u2013821","journal-title":"Blood Coagul Fibrinolysis"},{"key":"1623_CR107","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1213\/ane.0b013e31819bceb1","volume":"108","author":"N Mackman","year":"2009","unstructured":"Mackman N (2009) The role of tissue factor and factor VIIa in hemostasis. Anesth Analg 108:1447\u20131452","journal-title":"Anesth Analg"},{"key":"1623_CR108","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/107602960200800104","volume":"8","author":"K Presseizen","year":"2002","unstructured":"Presseizen K, Friedman Z, Shapiro H, Radnay J, Ellis MH (2002) Phosphatidylserine expression on the platelet membrane of patients with myeloproliferative disorders and its effect on platelet-dependent thrombin formation. Clin Appl Thromb Hemost 8:33\u201339","journal-title":"Clin Appl Thromb Hemost"},{"key":"1623_CR109","doi-asserted-by":"publisher","first-page":"4061","DOI":"10.1182\/blood-2008-06-164087","volume":"112","author":"M Marchetti","year":"2008","unstructured":"Marchetti M, Castoldi E, Spronk HM et al (2008) Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood 112:4061\u20134068","journal-title":"Blood"},{"key":"1623_CR110","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/ajh.21338","volume":"84","author":"E Arellano-Rodrigo","year":"2009","unstructured":"Arellano-Rodrigo E, Alvarez-Larr\u00e1n A, Reverter JC et al (2009) Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden. Am J Hematol 84:102\u2013108","journal-title":"Am J Hematol"},{"key":"1623_CR111","doi-asserted-by":"publisher","first-page":"4921","DOI":"10.1182\/blood-2011-09-376517","volume":"120","author":"JH Smalberg","year":"2012","unstructured":"Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW (2012) Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood 120:4921\u20134928","journal-title":"Blood"},{"key":"1623_CR112","doi-asserted-by":"publisher","first-page":"5617","DOI":"10.1182\/blood-2008-12-196014","volume":"113","author":"F Dentali","year":"2009","unstructured":"Dentali F, Squizzato A, Brivio L et al (2009) JAK2V617F mutation for the early diagnosis of Ph- myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood 113:5617\u20135623","journal-title":"Blood"},{"key":"1623_CR113","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00277-009-0788-5","volume":"89","author":"V Stefano De","year":"2010","unstructured":"De Stefano V, Za T, Rossi E et al; GIMEMA Chronic Myeloproliferative Neoplasms Working Party (2010) Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617Fmutation. Ann Hematol 89:141\u2013146","journal-title":"Ann Hematol"},{"key":"1623_CR114","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","volume":"110","author":"AM Vannucchi","year":"2007","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P et al (2007) Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110:840\u2013846","journal-title":"Blood"},{"key":"1623_CR115","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s00277-017-3040-8","volume":"96","author":"I Bertozzi","year":"2017","unstructured":"Bertozzi I, Bogoni G, Biagetti G et al (2017) Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden. Ann Hematol 96:1297\u20131302","journal-title":"Ann Hematol"},{"key":"1623_CR116","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1182\/blood-2011-02-339655","volume":"118","author":"M Panova-Noeva","year":"2011","unstructured":"Panova-Noeva M, Marchetti M, Buoro S et al (2011) JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. Blood 118:2599\u20132601","journal-title":"Blood"},{"key":"1623_CR117","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1160\/TH15-04-0320","volume":"115","author":"I Kogan","year":"2016","unstructured":"Kogan I, Chap D, Hoffman R et al (2016) JAK-2 V617F mutation increases heparanase procoagulant activity. Thromb Haemost 115:73\u201380","journal-title":"Thromb Haemost"},{"key":"1623_CR118","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1182\/blood-2012-01-404889","volume":"121","author":"V Rosti","year":"2013","unstructured":"Rosti V, Villani L, Riboni R et al (2013) Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. Blood 121:360\u2013368","journal-title":"Blood"},{"key":"1623_CR119","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, Kantarjian H, Mesa RA et al (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363:1117\u20131127","journal-title":"N Engl J Med"},{"key":"1623_CR120","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Passamonti F, Rambaldi A et al (2012) Long-term efficacy and safety results from a phase II study of Ruxolitinib in patients with polycythemia vera. ASH Annual Meeting. Abstract 120(21):804","DOI":"10.1182\/blood.V120.21.804.804"},{"key":"1623_CR121","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","volume":"123","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Ferretti V et al (2014) JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 123:1544\u20131551","journal-title":"Blood"},{"key":"1623_CR122","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","volume":"123","author":"G Rotunno","year":"2014","unstructured":"Rotunno G, Mannarelli C, Guglielmelli P et al (2014) Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 123:1552\u20131555","journal-title":"Blood"},{"key":"1623_CR123","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1182\/blood-2014-08-596676","volume":"124","author":"G Finazzi","year":"2014","unstructured":"Finazzi G, Carobbio A, Guglielmelli P et al (2014) Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. Blood 124:2611\u20132612","journal-title":"Blood"},{"key":"1623_CR124","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","volume":"124","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Pascutto C et al (2014) Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood 124:1062\u20131069","journal-title":"Blood"},{"key":"1623_CR125","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/leu.2014.343","volume":"29","author":"MC Finazzi","year":"2015","unstructured":"Finazzi MC, Carobbio A, Cervantes F et al (2015) CALR mutation, MPL mutation, and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis. Leukemia 29:1209\u20131210","journal-title":"Leukemia"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-018-1623-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-018-1623-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-018-1623-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:09:44Z","timestamp":1719792584000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-018-1623-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,6]]},"references-count":125,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["1623"],"URL":"https:\/\/doi.org\/10.1007\/s11239-018-1623-4","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,6]]},"assertion":[{"value":"6 February 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}